Loading...
•
Jun 30, 2020
Amedisys Q2 2020 Earnings Report
Amedisys reported a decrease in net service revenue but an increase in net income for Q2 2020, and reissued its full year 2020 guidance.
Key Takeaways
Amedisys reported a decrease in net service revenue to $485.0 million compared to $493.0 million in 2019. Net income attributable to Amedisys, Inc. increased to $34.7 million compared to $33.7 million in 2019. The company reissued its full year 2020 guidance, anticipating net service revenue in the range of $2.040 billion to $2.070 billion and adjusted diluted earnings per share in the range of $4.84 to $5.06.
Net service revenue decreased to $485.0 million compared to $493.0 million in 2019.
Net income attributable to Amedisys, Inc. increased to $34.7 million compared to $33.7 million in 2019.
Adjusted net income attributable to Amedisys, Inc. per diluted share was $1.34 compared to $1.21 in 2019.
The company reissued its full year 2020 guidance.
Amedisys
Amedisys
Forward Guidance
Amedisys anticipates net service revenue to be in the range of $2.040 billion to $2.070 billion. Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million. Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06 based on an estimated 33.4 million shares outstanding. This guidance excludes the effects of any future acquisitions, if any are made.
Positive Outlook
- Net service revenue is anticipated to be in the range of $2.040 billion to $2.070 billion.
- Adjusted EBITDA is anticipated to be in the range of $245 million to $255 million.
- Adjusted diluted earnings per share is anticipated to be in the range of $4.84 to $5.06.
- Guidance is based on an estimated 33.4 million shares outstanding.
- The guidance excludes the effects of any future acquisitions.
Challenges Ahead
- The home health, hospice and personal care industries are highly competitive.
- The industries are subject to intensive regulations.
- Trends are subject to numerous factors, risks, and uncertainties.
- The guidance excludes the effects of any future acquisitions, if any are made.
- Forward-looking statements are inherently subject to risks and uncertainties.